Pharma’s GLP-1 Gold Rush Starts Looking Suspiciously Like a Bubble About to Pop
Pharma found its golden needle, and now everyone’s chasing the same vein. Novo NordiskNVO and Eli LillyLLY are leading the charge with GLP-1 hits like Wegovy and Zepbound, driving a surge in profits and pushing R&D returns to multi-year highs. But as more capital and pipelines flood the space, the whole run is starting to resemble a “bubble effect.”
Concentration overload: Projected R&D returns for the world’s top 20 pharma companies rose to 7% in 2025, building on a steady climb from 5.9% in 2024. However, if you take out GLP-1 and GIP assets, that number drops to 2.9%. It shows how much the industry’s momentum is riding on weight loss and diabetes drugs. As Deloitte’s Hanno Ronte said, “It is a bubble, because so much is concentrated,” with just 9% of the pipeline set to drive nearly 70% of peak sales.
- Obesity drugs overtook oncology as the top late-stage pipeline driver for the first time in 16 years, taking ~25% of forecast sales vs. oncology’s 20%.
- Average peak sales per asset climbed to $598M from $510M, with most of the jump coming from a handful of high-forecast GLP-1 drugs.
Medicare Access Could Supercharge Demand
Donald Trump’s move to make GLP-1 drugs available to Medicare patients starting July 1 could pour fuel on an already overheated market. The policy shift opens the door to 66M+ seniors, setting up another wave of demand that could stretch valuations further — or bring the bubble’s peak closer. At the same time, development costs have climbed, raising the bar for commercial success even as companies double down on obesity-focused pipelines.
- Beyond those pipelines, GLP-1 is expanding into new uses, with Novo Nordisk’s semaglutide showing promise in heart, liver, kidney, and addiction, though an Alzheimer’s trial missed.
- That expansion could deepen the industry’s reliance, leaving it exposed to shocks where any safety signal or supply disruption could ripple across the sector.
Surfing the wave: Deloitte’s Hanno Ronte summed up the dilemma for pharma execs — when you’re riding a lucrative wave with a crowded field, there’s barely any room to maneuver. That leaves companies choosing between doubling down on the GLP-1 rush or putting money into the next breakthrough. With pricing pressure rising, competition tightening, and regulators closing in, the trade is becoming a high-stakes bet that might only hold as long as the momentum does.